Clinical Trials

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials in collaboration with the University of Texas MD Anderson Cancer Center in Houston, USA to deliver the power of T cells to cancer patients. The purpose of these trials is to develop innovative personalized immunotherapies aimed at targeting a patient’s tumor selectively and effectively. Other centers in the United States and Europe are planning to conduct these clinical trials in the future.

The following four clinical trials are currently open and recruiting patients at MD Anderson Cancer Center:

More information on all the clinical trials conducted at the MD Anderson Cancer Center can be found here.

If you are a patient and interested participating in one of Immatic’s clinical trials, please speak to your treating physician.

We use cookies to ensure that we give you the best experience on our website.